Immuron vs Rani Therapeutics
IMRN and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMRN and RANI compare
Rani Therapeutics grew revenue faster over the last twelve months (449% versus 5.9% for Immuron).
Immuron keeps more of each dollar of sales as profit, with a net margin of −47.7% compared with −493% at Rani Therapeutics.
Immuron scores higher on the StockData Score (4 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMRN | RANI |
|---|---|---|
| Size and price | ||
| Market cap | – | $73.4M |
| Share price | $0.875 | $0.526 |
| Change, 1 year | −45.6% | −75.2% |
| Change, 5 years | −74.6% | −98.5% |
| Beta (5Y) | 0.37 | 0.85 |
| Employees | 7 | 69 |
| StockData Score | ||
| Total score | 4 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 11.1× |
| P/B | – | 2.2× |
| FCF yield | – | −31.7% |
| Fair value | – | $0.366 |
| Margin of safety | – | −43.8% |
| Growth | ||
| Revenue growth (TTM) | 5.9% | 449% (better) |
| Revenue growth, 5Y average | 121% (better) | 28.7% |
| Profitability | ||
| Gross margin | 64.5% | – |
| Operating margin | −49.9% (better) | −530% |
| Net margin | −47.7% (better) | −493% |
| FCF margin | −42.3% (better) | −353% |
| Return on equity | – | −249% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Interest coverage | −261.7× | −71.9× (better) |
| Current ratio | 7.26 (better) | 5.26 |
| Altman Z-score | – | −1.36 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.02% | 32.7% |
| Held by insiders | 1.9% | 30.6% |
| Insider net buying, 12 months | – | $49.7K |
| Short interest, % of float | – | 8.5% |
Go deeper
- IMRN stock overview
- IMRN income statement
- IMRN valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.